Program
ranosidenib
Also written as “HMPL-306”, “HMPL-306 tablet” and “HMPL-306 Regimen”.
Its studies are mostly in Leukemia, Myeloid, Acute · Astrocytoma · Cholangiocarcinoma · Glioma, led by HUTCHMED.
Furthest: phase 3, since Apr 16, 20247 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HUTCHMED | 73 open or running | phase 3since Apr 16, 2024 | Feb 13, 2020 | Dec 2026phase 1 · NCT07025018 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 13, 2020First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04272957 · 75 enrolled · China
- Jan 19, 2021Phase 1 study in Leukemia, Myeloid, AcuteNCT04764474 · 46 enrolled · United States, Spain
- Feb 6, 2021Phase 1 study in CholangiocarcinomaNCT04762602 · 42 enrolled · United States, Spain
- Apr 16, 2024Phase 3 study in Leukemia, Myeloid, AcuteNCT06387069 · 316 planned · China
- Oct 29, 2024Phase 1 study in Mass Balance StudyNCT06671873 · 6 enrolled · China
- May 28, 2025Phase 1 study in GliomaNCT07025018 · 52 planned · China
- Oct 19, 2026Phase 3 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07912398 · 210 planned
Ahead
- Dec 2026Primary completion: phase 1 study in GliomaNCT07025018
- Dec 31, 2028Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT06387069
- Mar 2032Primary completion: phase 3 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07912398
TargetBeta
“An orally bioavailable inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07912398Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | 3 | Not yet recruiting | Mar 2032 | 210 |
| NCT07025018Glioma · China | 1 | Recruiting | Dec 2026 | 52 |
| NCT06671873Mass Balance Study · China | 1 | Completed | Feb 28, 2025 | 6 |
| NCT06387069Leukemia, Myeloid, Acute · China | 3 | Recruiting | Dec 31, 2028 | 316 |
| NCT04762602Cholangiocarcinoma · United States, Spain | 1 | Terminated | Feb 27, 2025 | 42 |
| NCT04764474Leukemia, Myeloid, Acute · United States, Spain | 1 | Terminated | Jan 15, 2025 | 46 |
| NCT04272957Leukemia, Myeloid, Acute · China | 1 | UNKNOWN | Jun 30, 2021 | 75 |
How it is read
Names in the registry
- “HMPL-306”, 4 entries
- “HMPL-306 tablet”, 1 entry
- “HMPL-306 Regimen”, 1 entry
- “100 µCi [14C] HMPL-306”, 1 entry
Codes read as this program: HMPL306.
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Astrocytoma, 1 study
- Cholangiocarcinoma, 1 study
- Glioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.